Trials / Recruiting
RecruitingNCT07180056
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Efficacy and Safety of Adjuvant CDK4/6 Inhibitors in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: a Real-world Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 229 (estimated)
- Sponsor
- Wenjin Yin · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDK4/6 inhibitor | abemaciclib OR ribociclib |
Timeline
- Start date
- 2025-08-28
- Primary completion
- 2028-02-01
- Completion
- 2033-02-01
- First posted
- 2025-09-18
- Last updated
- 2025-11-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07180056. Inclusion in this directory is not an endorsement.